Laguna Tech

Executive Summary

Laguna Tech is a privately held medical device company based in Irvine, CA, focused on developing the ZETA Transcatheter Aortic Valve System, a novel balloon-expandable valve designed to treat both aortic regurgitation (AR) and aortic stenosis. Unlike current transcatheter aortic valve replacement (TAVR) devices that are primarily indicated for stenosis, the ZETA system addresses the significant unmet need in AR, which affects approximately 1 in 8 people over 75 with valvular heart disease. The device is currently for investigational use only and has not received FDA approval. Founded in 2019, Laguna Tech operates in a competitive TAVR market dominated by established players, but its dual-indication design could offer a differentiated solution. The company's progress is constrained by limited public information on funding, clinical milestones, or commercialization timelines, indicating an early-stage profile with high regulatory and execution risk.

Upcoming Catalysts (preview)

• Q3 2026FDA Investigational Device Exemption (IDE) Approval60% success
• Q4 2026First-In-Human Clinical Trial Initiation50% success